Radiation-agent combinations for glioblastoma: challenges in drug development and future considerations.

ABSTRACT: Glioblastoma is an aggressive disease characterized by moderate initial response rates to first-line radiation-chemotherapy intervention followed by low poor response rates to second-line intervention. This article discusses novel strategic platforms for the development of radiation-investigational agent combination clinical trials for primary and recurrent glioblastoma in a NCI-NCTN settings with simultaneous analysis of challenges in the drug development process.

SUBMITTER: Kunos CA 

PROVIDER: S-EPMC5709276 | biostudies-literature | 2017 Sep

REPOSITORIES: biostudies-literature